What Are FDCs (Fixed-Dose Combinations) and Why Is India Banning Irrational Supplement Blends? A Guide to Safer Formulations (2026)

A Fixed-Dose Combination (FDC) is defined as a pharmaceutical product that contains two or more active pharmacological ingredients combined in a fixed ratio within a single dosage form — such as a tablet, capsule, syrup, or injection. When the combination is rational and evidence-backed, FDCs genuinely help patients. When it is not, they expose people to unnecessary side effects, mask underlying conditions, and — in the case of antibiotic FDCs — accelerate antimicrobial resistance. India's June 2026 ban on 16 more FDC drugs is the latest chapter in a decade-long regulatory reckoning that has now removed more than 800 such combinations from the market.

The same regulatory logic that governs prescription FDCs is increasingly relevant to the supplement industry. Multi-ingredient blends — whether sold as "immunity boosters," "skin glow" capsules, or "digestive enzymes" — face the same fundamental question every banned FDC failed to answer: does the combination actually work better than its individual parts, and is it safe to take them together?

At a Glance: Rational vs. Irrational FDCs — Key Differences

Feature	Rational FDC	Irrational FDC
Clinical evidence	Randomised controlled trials or solid observational data support the combination	No adequate clinical studies; combination assumed, not proven
Therapeutic synergy	Each ingredient addresses a different, complementary mechanism (e.g., TB drug regimens)	Ingredients act on unrelated pathways with no additive benefit (e.g., antibiotic + enzyme)
Dose flexibility	Fixed ratio is clinically appropriate for most patients	Fixed ratio may over- or under-dose individual components for different patients
Adverse effect profile	Known, manageable, and outweighed by benefit	Compounded or unpredictable; harder to identify which ingredient caused a reaction
Regulatory status (India, 2026)	Approved by DTAB/CDSCO with documented therapeutic justification	Banned under Section 26A of the Drugs and Cosmetics Act, 1940
Antimicrobial resistance risk	Low (when antibiotics are used with scientific justification)	High — irrational antibiotic FDCs are a documented driver of AMR

What Exactly Is an FDC and How Does It Differ from a Single-Drug Product?

An FDC is defined as any formulation in which two or more active drugs are present in a single unit dose. The key word is fixed: the ratio of Drug A to Drug B cannot be adjusted without switching to a different product entirely. This constraint creates both advantages and limitations.

The appeal is straightforward. A patient managing tuberculosis might need to take four separate drugs daily. Combining them into one or two tablets dramatically reduces pill burden, which in turn improves adherence — a critical factor in TB outcomes. HIV antiretroviral regimens and certain hypertension protocols follow the same logic, where multi-drug combinations are not just convenient but clinically superior to sequential monotherapy.

The limitation is equally clear. If a patient is allergic to one ingredient in an FDC, the entire product must be stopped, making it difficult to identify the culprit. If one drug requires dose escalation but the other does not, the fixed ratio becomes a clinical straitjacket. And if the two drugs in the combination simply do not have a documented pharmacological reason to be together, the patient absorbs the risk profile of both drugs with no additional therapeutic gain.

The Hindu's editorial on the June 2026 ban frames this precisely: "All patients may not actually need all the drugs in the combination, exposing them to unnecessary side effects."

Why Has India Banned So Many FDCs Since 2016?

India's FDC problem stems partly from a regulatory gap that persisted for decades. State drug controllers could approve FDCs independently, without central oversight from the Central Drugs Standard Control Organisation (CDSCO). This created a market flooded with combinations that had never been subjected to rigorous clinical review. Pharmaceutical companies found FDCs commercially attractive — a new combination could be patented and marketed as a novel product even when the individual drugs were long off-patent.

By the mid-2010s, the scale of the problem became undeniable. In March 2016, the Union Ministry of Health banned 344 FDCs in a single order, citing irrationality and lack of therapeutic justification. Pharmaceutical companies challenged the ban in court. Rather than simply reinstating or striking down the ban, the Supreme Court of India directed a fresh scientific review by the Drugs Technical Advisory Board (DTAB) — an expert body constituted under the Drugs and Cosmetics Act, 1940.

Based on DTAB's recommendations, the government re-imposed bans on 328 FDCs and restricted six others in September 2018. Reviews continued through the early 2020s. In 2024, 156 additional FDCs were banned, including commonly used cough, cold, fever, and pain medicines — products that had been household staples for years. The June 2026 order adds 16 more to the list, covering dermatological drugs, analgesics, antispasmodics, and antibiotic-based formulations.

More than 800 FDCs have been removed from the Indian market in a decade, all on the same grounds: lack of clinical efficacy, no real therapeutic value, and documented or foreseeable risks to patient safety.

Which Specific Combinations Were Banned in June 2026 and Why?

The June 2026 ban targets three broad categories: antibiotic-based combinations, analgesic/antispasmodic combinations, and dermatological formulations. Doctors who spoke to The Hindu after the ban provided concrete explanations for why specific combinations were flagged.

Amoxicillin + Serratiopeptidase exemplifies an irrational antibiotic FDC. Amoxicillin is a beta-lactam antibiotic that kills bacteria by disrupting cell wall synthesis. Serratiopeptidase is a proteolytic enzyme marketed for its supposed anti-inflammatory properties. The two drugs act on entirely different biological targets. No clinical evidence shows that adding serratiopeptidase to amoxicillin improves infection outcomes, and combining them creates a product that is harder to dose rationally. Dr. Sumit Aggarwal, Director and Head of Internal Medicine at Sarvodaya Hospital, described the combination as lacking "adequate scientific justification."

Cefuroxime + Serratiopeptidase and Cefadroxil + Probenecid were similarly flagged. Probenecid is a uricosuric agent used in gout management; its combination with cefadroxil (a cephalosporin antibiotic) in a fixed ratio makes little pharmacological sense for most clinical scenarios.

Dicyclomine + Paracetamol + Clidinium Bromide represents the antispasmodic/analgesic category. Dicyclomine is an anticholinergic antispasmodic used for gut cramps. Paracetamol is a general analgesic and antipyretic. Clidinium bromide is another anticholinergic. Dr. Neetu Jain, Senior Consultant in Pulmonology, Critical Care and Sleep Medicine at PSRI Hospital, explained that combining an antispasmodic with paracetamol "does not make sense" — the drugs address different symptoms through different mechanisms, and the fixed combination means patients who need only one component are automatically exposed to the other.

Dicyclomine + Chlordiazepoxide raised particular concern because chlordiazepoxide is a benzodiazepine — a sedative used for anxiety and depression. Combining a benzodiazepine with an antispasmodic in a fixed ratio, without individualized psychiatric assessment, is a significant patient safety risk.

Dermatological combinations involving Ayurvedic oils with Vitamin E, Vitamin A, and glycerine were also targeted. Dr. Manish Jangra, Consultant Dermatologist at Healing Hands Multispeciality Clinic, noted that "there are no clinical studies proving the efficacy of mixing elements such as Ayurvedic oils with Vitamin E, Vitamin A, glycerine etc." and that some combinations could increase the risk of irritant contact dermatitis and allergic contact dermatitis.

What Is the Link Between Irrational FDCs and Antimicrobial Resistance?

Antimicrobial resistance (AMR) is defined as the ability of microorganisms — bacteria, viruses, fungi, and parasites — to resist the effects of medicines that once killed them or inhibited their growth. It ranks among the most serious global public health threats of the 21st century, and India carries a disproportionate share of the burden.

Irrational antibiotic FDCs contribute to AMR through several mechanisms. First, they encourage inappropriate antibiotic use: a patient with a viral infection who takes an antibiotic FDC (perhaps because it also contains a painkiller or an enzyme) is exposing their microbiome to an antibiotic with no therapeutic benefit. Second, sub-therapeutic dosing — which can occur when the fixed ratio is not optimized for the patient's weight, renal function, or infection severity — allows bacteria to survive and develop resistance. Third, the sheer volume of antibiotic FDCs on the Indian market historically made it easier for both patients and prescribers to reach for combination products rather than targeted monotherapy.

The Hindu's editorial notes that in the 2016 ban alone, 19% of the 330 FDCs banned were antibiotics, and that "there is enough evidence to show that irrational antibiotic FDC drug usage leads to or exacerbates the growing antimicrobial resistance problem in the country."

For supplement buyers, the AMR angle is a reminder that "natural" or "herbal" does not automatically mean safe or rational. Combinations that include antimicrobial herbs (such as neem, berberine, or oregano oil) alongside other active ingredients raise the same questions: Is the combination dose appropriate? Is there evidence of synergy? Could indiscriminate use contribute to resistance in gut microbiota?

How Does the Regulatory Process for Banning an FDC Actually Work in India?

The legal basis for FDC bans in India is Section 26A of the Drugs and Cosmetics Act, 1940, which empowers the Central Government to prohibit the manufacture, sale, or distribution of any drug if it is satisfied that the drug is likely to involve risk to human beings or animals or does not have the therapeutic value claimed for it.

The process, as refined by the Supreme Court's 2017 intervention, now involves several steps. The Drugs Technical Advisory Board — India's apex statutory body for drug regulation — constitutes an expert sub-committee to review the clinical and scientific evidence for each FDC under scrutiny. The sub-committee examines published clinical trials, pharmacological rationale, adverse event data, and international regulatory precedents. Manufacturers are given an opportunity to submit evidence in favour of their products.

Based on the sub-committee's findings, DTAB recommends whether a ban, restriction, or continued approval is appropriate. The Union Ministry of Health and Family Welfare then issues a gazette notification under Section 26A. The ban takes immediate effect, and all State Drug Controllers, regulatory authorities, and enforcement agencies are directed to ensure compliance. Manufacturers, importers, distributors, and pharmacies are instructed to stop stocking and selling the banned FDCs.

The enforcement step is where the system has historically struggled. The Hindu's editorial acknowledges that "in many instances in the past, stocks of banned drugs were still being sold in pharmacies, because the message had not percolated down." Dr. Jangra echoed this concern specifically for dermatological FDCs: "Many times, companies change the FDC and re-launch. There is poor enforcement and patients avoiding proper treatment and care adds to the problem."

What Does This Mean for Supplement Blends Sold in India?

The regulatory framework described above applies specifically to drugs under the Drugs and Cosmetics Act. Supplements — including vitamins, minerals, herbal extracts, and nutraceuticals — are governed by a different, and generally less stringent, set of rules under the Food Safety and Standards Authority of India (FSSAI). This regulatory gap means that many multi-ingredient supplement blends currently on the Indian market have never been subjected to the kind of rigorous clinical review that led to the FDC bans.

This does not mean all supplement blends are irrational or unsafe. But it does mean that the burden of proof falls on the buyer to ask the same questions that DTAB asks about FDCs:

Is there clinical evidence for the specific combination, not just for the individual ingredients in isolation?
Does the fixed ratio make pharmacological sense — are the doses of each ingredient appropriate for the intended effect?
Could any ingredient in the blend interact adversely with medications the user is already taking?
Is the manufacturer transparent about the source and quality of each ingredient?

Consider a common example: a "liver support" supplement combining milk thistle (silymarin), N-acetylcysteine (NAC), and turmeric (curcumin). Each of these has some evidence for hepatoprotective effects individually. But the specific combination, at specific doses, in a fixed ratio, may not have been tested in a clinical trial. The interaction between curcumin and NAC at high doses, for instance, is not well characterized. A consumer buying this product is, in a limited sense, participating in an uncontrolled experiment.

The same logic applies to skin supplements combining Ayurvedic botanicals with fat-soluble vitamins — precisely the category flagged in the June 2026 FDC ban. If you are considering a supplement for skin health, the evidence base for individual ingredients like neem and manjistha is worth examining separately before assuming a multi-herb blend is superior.

Are There Rational Multi-Ingredient Formulations? What Makes a Blend Legitimate?

Yes — and the distinction matters. Not all combination products are irrational. The same DTAB process that bans irrational FDCs has also validated numerous rational combinations. A rational FDC meets several criteria: each ingredient addresses a different mechanism relevant to the same clinical condition, or one ingredient enhances the bioavailability or tolerability of another. The combination, at the specific doses used, has been tested in adequately powered clinical trials and shown to be superior to monotherapy or placebo. The dose ratio is appropriate for the target population without requiring individual titration for most patients. And the adverse effect profile is known, manageable, and outweighed by the clinical benefit.

Tuberculosis drug regimens are the canonical example: isoniazid, rifampicin, pyrazinamide, and ethambutol each target different aspects of Mycobacterium tuberculosis biology, and their combination is not just convenient but essential for preventing resistance. HIV antiretroviral combinations follow the same logic.

In the supplement space, rational combinations do exist. Magnesium glycinate combined with a small amount of vitamin B6 (pyridoxine) has some evidence for improved magnesium absorption and utilization — though even here, the evidence is not as solid as for pharmaceutical FDCs. If you are evaluating magnesium glycinate products for sleep support, checking whether any added co-factors have documented synergy with magnesium is a reasonable due-diligence step.

Similarly, berberine combined with chromium for blood sugar management has a plausible pharmacological rationale — both affect glucose metabolism through partially overlapping pathways — but the clinical evidence for the specific combination is thinner than for berberine alone. The evidence-based protocol for berberine use in India is worth reviewing before assuming a combination product offers additional benefit.

What Should Patients Do If They Are Currently Taking a Banned FDC?

Doctors who spoke to The Hindu following the June 2026 ban were consistent on one point: do not stop treatment abruptly without consulting a physician. Dr. Vikram Jeet Singh, Senior Director of Internal Medicine at Aakash Healthcare, warned that "when medicines are taken indiscriminately, they can expose patients to unnecessary side effects, increase the risk of adverse drug reactions and mask underlying illnesses."

The practical steps are straightforward. Identify whether your medication is on the banned list by checking the Ministry of Health's gazette notification or asking your pharmacist. Consult your prescribing doctor before making any changes. In most cases, a suitable alternative — either a single-ingredient product or a rational FDC — will be available. Do not self-substitute with over-the-counter alternatives or supplement blends marketed as "natural" equivalents. The underlying condition that prompted the original prescription still needs to be managed. If you experienced problems with a banned FDC, report adverse effects to the pharmacovigilance system. This data helps regulators refine future decisions.

For supplement users rather than prescription drug patients, the advice is analogous: if you are taking a multi-ingredient blend that you cannot find clinical evidence for, it is worth discussing with a healthcare provider whether the combination is actually serving your health goals or simply adding ingredient complexity without benefit.

Why Does Enforcement Remain the Weakest Link in India's FDC Regulation?

The regulatory science behind India's FDC bans is, by most expert assessments, sound. The DTAB process involves genuine expert review, manufacturers are given an opportunity to present evidence, and the Supreme Court's oversight has added a layer of judicial accountability. The problem lies in implementation.

India has over 800,000 retail pharmacies, many of them small, independently operated shops in tier-2 and tier-3 cities and rural areas. When a ban is notified in the central gazette, the information must travel through state drug controllers to district-level inspectors to individual pharmacies — a chain with multiple points of failure. Stocks of banned drugs can remain on shelves for months. Some manufacturers reformulate slightly and relaunch under a different name, exploiting the lag between market surveillance and regulatory action.

The Hindu's editorial calls for the government to "activate its monitoring and supervision arm to ensure that the benefits from the ban reach the last mile." Dr. Jangra's observation about dermatological FDCs — that companies "change the FDC and re-launch" — points to a specific enforcement gap that requires proactive market surveillance, not just reactive banning.

For consumers, this enforcement gap means that a product being available at a pharmacy is not evidence that it is currently legal or safe. Checking the CDSCO's publicly available list of banned drugs before purchasing any combination product — prescription or OTC — is a reasonable precaution.

How Should Supplement Buyers Apply the FDC Lesson to Their Purchasing Decisions?

The FDC regulatory story offers a practical framework for evaluating any multi-ingredient health product, whether it is a prescription drug or a supplement blend sold at a health store.

Ask for the evidence, not the ingredient list. A long list of ingredients is not a sign of quality — it is a sign of complexity. The relevant question is whether the specific combination, at the specific doses in the product, has been tested in humans and shown to work. A supplement with three well-studied ingredients at evidence-backed doses is almost always preferable to one with fifteen ingredients at sub-therapeutic doses.

Understand the mechanism. If you cannot find a plausible pharmacological reason why Ingredient A and Ingredient B should be combined — if they act on unrelated pathways with no documented synergy — treat the combination with the same skepticism that DTAB applied to amoxicillin + serratiopeptidase.

Check for interactions. Fixed-ratio combinations make it impossible to adjust the dose of one ingredient without changing the dose of all others. If you are taking other medications or supplements, a combination product multiplies the number of potential interactions to check.

Prefer transparency. Manufacturers who publish their clinical evidence, disclose their ingredient sources, and use third-party testing are operating closer to the standard that rational FDC manufacturers are held to. Those who rely on vague claims about "synergistic blends" or "proprietary formulas" are not.

Consider single-ingredient products first. If you are exploring Arjuna for heart health or carb blockers for glucose control, starting with a well-characterized single ingredient allows you to assess your individual response before adding complexity. This mirrors the clinical logic behind titrating individual drugs before combining them.

What Is the Broader Significance of India's FDC Crackdown for Global Health Policy?

India is the world's largest producer of generic medicines and a major supplier to low- and middle-income countries. The quality and rationality of drugs manufactured in India therefore has global implications. An irrational FDC banned in India may still be exported to markets with weaker regulatory oversight. Conversely, India's increasingly rigorous approach to FDC regulation — driven by Supreme Court oversight, DTAB expertise, and civil society pressure — is a model that other emerging-market regulators are watching.

The research literature on the impact of India's FDC bans notes that the 2024 and 2026 waves of bans are particularly significant because they target not just obscure combination products but mainstream, widely-prescribed medicines that had become embedded in clinical practice. Changing prescribing habits for products that doctors and patients have used for years requires not just regulatory action but physician education and patient communication — areas where India's health system still has significant work to do.

Dr. Lakshman Ramachandran, Consultant Physician at Kailash Hospital, captured the positive framing: the latest government move "will help ensure that patients receive therapies that are scientifically validated, safer, and more effective." That is the standard — scientifically validated, safer, more effective — that every multi-ingredient health product, whether a prescription FDC or a supplement blend, should be held to.

The FDC bans are not an argument against combination therapy. They are an argument for evidence. When the evidence supports a combination, as it does for TB regimens and HIV antiretrovirals, fixed-dose combinations save lives. When the evidence is absent, as it was for hundreds of products removed from Indian pharmacies over the past decade, the combination is not a treatment — it is a risk.